COPD (chronic obstructive pulmonary disease) causes chronic oxygen deprivation, and HBOT dramatically increases available oxygen, so they seem like a natural pairing. The reality is considerably more complicated, and for some COPD patients, HBOT carries meaningful risks rather than benefits. Understanding the distinction between oxygen supplementation (which COPD patients often use) and hyperbaric oxygen therapy (a very different intervention) is the starting point.1 It is one of several chronic conditions that may benefit from hyperbaric therapy that researchers are actively investigating.
What COPD Is and Why HBOT Is Complicated
COPD is characterized by irreversible airflow limitation due to emphysema (destruction of alveolar walls), chronic bronchitis, or both. Emphysematous lungs trap air, and damaged alveoli can form bullae (large air-filled sacs). During pressurization in a hyperbaric chamber, this trapped air becomes a serious problem: as pressure increases, trapped air cannot equilibrate, creating risk of alveolar rupture and pneumothorax (collapsed lung).
This is not a minor concern. Pneumothorax is a contraindication to HBOT (unless the patient is already on a chest tube), and untreated emphysema with bullae is a significant risk factor. This means the very patients who might intuitively seem to benefit most from additional oxygen therapy (those with severe emphysema and chronic hypoxia) are often the least safe candidates for HBOT.
Oxygen Supplementation vs. Hyperbaric Oxygen
A crucial distinction: supplemental oxygen therapy (using an oxygen concentrator or tank to breathe enriched air at normal atmospheric pressure) is a mainstay of COPD management for patients with significant resting hypoxemia. This is physiologically and practically different from HBOT in a pressurized chamber. The risks that HBOT poses (barotrauma, oxygen toxicity at high partial pressures, pressure equalization requirements) don’t apply to standard supplemental oxygen.
COPD patients should not conflate these two modalities or assume that because supplemental oxygen helps them, HBOT would simply provide more of the same benefit at higher intensity.
Safety Assessment Before Any HBOT in COPD
For a COPD patient who has another indication for HBOT (such as a diabetic wound or radiation injury), careful pulmonary evaluation is mandatory before proceeding. This includes:
Pulmonary function testing to assess the degree of airflow limitation and air trapping. CT scan of the chest to identify bullae and assess emphysema extent. Assessment of carbon dioxide retention, as CO2 retainers require specific HBOT protocols. Pulmonologist clearance. In COPD patients with large bullae or severe emphysema, HBOT may be contraindicated even for otherwise approved indications.
The side effects and contraindications guide covers pulmonary contraindications in detail and is essential reading for any COPD patient considering HBOT.
CO2 Retention and HBOT
Many COPD patients, particularly those with advanced disease, develop chronic CO2 retention (hypercapnia). Their respiratory drive may shift from the normal oxygen-based stimulus to a CO2-based drive. When these patients breathe very high concentrations of oxygen, they can theoretically suppress their respiratory drive, worsening CO2 retention and causing hypercapnic respiratory failure.
This concern is managed in HBOT settings through careful monitoring and protocol adjustment, but it requires awareness and expertise. HBOT at a facility that lacks experience managing COPD patients is riskier than at a hospital-based program with respiratory medicine backup.
What Does the Research Say?
Clinical research specifically on HBOT for COPD management is very limited. One small study of 98 stable COPD patients found that the HBOT group showed significantly improved arterial blood gas indexes, pulmonary function, and quality-of-life scores compared to control (all P < 0.05).2 This came from a single trial, and HBOT is not recommended by any major pulmonology guideline for COPD.
An animal study at 1.3 ATA showed significant increases in antioxidant enzyme activity and decreases in inflammatory cell expression in lung tissue in COPD models.3 These findings are preclinical and do not establish clinical benefit.
In a study of 98 stable COPD patients, those who received HBOT showed improved arterial blood gas indexes and pulmonary function scores compared to controls (P < 0.05), but this is a single small trial and does not change the relative contraindication status.2
Peer-reviewed research
COPD Patients Who May Qualify for HBOT
Despite the concerns above, some COPD patients can receive HBOT safely for other indications when properly evaluated. A COPD patient with a diabetic foot ulcer or radiation-induced wound injury may still qualify for HBOT if pulmonary assessment shows manageable risk. The decision requires collaboration between the pulmonologist, the hyperbaric physician, and potentially the patient’s primary care team.
The wound healing and HBOT and diabetes and HBOT articles cover situations where COPD patients might legitimately receive HBOT for non-respiratory indications.
What Actually Helps COPD
Evidence-based COPD management includes: smoking cessation (the single most effective intervention at any stage), bronchodilator medications (short- and long-acting), inhaled corticosteroids for appropriate patients, long-term supplemental oxygen for those with significant resting hypoxemia, pulmonary rehabilitation (exercise training and education), and surgical interventions (lung volume reduction surgery or transplant for selected severe cases). None of these involve HBOT, and HBOT should not be pursued as an alternative to these established treatments.
Understanding the Difference Between Hypoxemia Management and HBOT
COPD patients and their families sometimes confuse oxygen supplementation with HBOT because both involve extra oxygen. The distinction is fundamental. Supplemental oxygen therapy for COPD delivers 24 to 40 percent oxygen at normal atmospheric pressure (1 ATA), gently correcting resting hypoxemia while the patient goes about their day. HBOT delivers 100 percent oxygen at 2.0 or more ATA in a sealed pressurized hard chamber, dramatically increasing both the partial pressure of oxygen and the physical pressure experienced by all body cavities including the lungs.
For a COPD patient with air trapping and bullae, this pressure difference is critical. Supplemental oxygen doesn’t pressurize the thorax; HBOT does. The physical compression and decompression of the hyperbaric cycle creates risks for trapped-air-containing structures that home oxygen use does not. This is why the two therapies cannot be equated in terms of safety or appropriateness for COPD patients.
Pulmonary Rehabilitation vs. HBOT for COPD
Pulmonary rehabilitation is the most evidence-based non-pharmacological intervention for COPD, with a strong evidence base for improving exercise capacity, quality of life, and hospitalizations. If you have COPD and are seeking treatments beyond medication, pulmonary rehabilitation is the appropriate first step and is covered by Medicare and most commercial insurers for eligible patients. HBOT is not in the same evidence category for COPD and should not be pursued instead of, or before, pulmonary rehabilitation has been tried and optimized.
Talking to Your Pulmonologist About HBOT
If you have another condition that qualifies for HBOT (wound healing, radiation injury, etc.) and also have COPD, your pulmonologist is the key person to involve in the safety evaluation. Bring your pulmonologist’s contact information and recent spirometry results to your hyperbaric medicine consultation. A coordinated evaluation between the two specialists, with clear communication about your lung function status, current medications, and the clinical urgency of the HBOT indication, will result in the safest and most appropriate treatment decision.
Optimizing COPD Management Before Any HBOT Consideration
For COPD patients considering HBOT for any indication, the starting point should always be optimizing COPD management itself. This means confirming that bronchodilator therapy is appropriate and adherence is good, checking whether inhaler technique is correct (a common and correctable source of suboptimal control), addressing any reversible triggers (continued smoking cessation, allergen avoidance, respiratory infection prevention with influenza and pneumococcal vaccines), managing comorbidities that worsen COPD symptoms (heart failure, sleep apnea, pulmonary hypertension), and confirming whether pulmonary rehabilitation has been offered and completed.
A COPD patient with poor baseline control presents higher risks and fewer physiological reserves for HBOT than a well-optimized COPD patient. Improving COPD control before HBOT not only reduces risk but may also reduce the urgency of pursuing any adjunct therapy by improving quality of life through better primary disease management.
An animal study at 1.3 ATA showed significant increases in SOD enzyme activity (P < 0.05) and decreases in inflammatory cell expression in lung tissue (P = 0.029) in COPD models, but these results are preclinical only.3
Peer-reviewed research
Frequently Asked Questions
I use supplemental oxygen at home for COPD. Does that mean I'm a candidate for HBOT?
No. Home supplemental oxygen and hyperbaric oxygen therapy are different interventions. COPD requiring supplemental oxygen does not make you a candidate for HBOT; in fact, the underlying lung disease may create risks that make HBOT inappropriate. A pulmonologist and hyperbaric physician need to evaluate your specific lung function before any HBOT consideration.
Can HBOT improve my lung function in COPD?
No. HBOT cannot reverse the structural damage (emphysema, bronchitis) that causes COPD. It cannot restore destroyed alveoli or reverse airway remodeling. There is no evidence that HBOT improves spirometry or other lung function measures in COPD patients with a basis strong enough to change clinical guidelines.
Is HBOT safe after a COPD exacerbation?
Immediately after a COPD exacerbation, when the patient may be unstable and the lungs inflamed and air-trapping, HBOT would be particularly risky. At minimum, the patient should be clinically stable, back to baseline function, and fully evaluated by a pulmonologist before any HBOT consideration for another indication.
What about mild HBOT (1.3 ATA soft chambers) for COPD?
The pressure increase in mild HBOT soft chambers (1.3 ATA) is lower than hard-shell medical chambers, which somewhat reduces barotrauma risk. There is no clinical evidence that mild HBOT provides meaningful benefit for COPD, and the fundamental concerns about air trapping and oxygen management in COPD still apply. It should not be used without physician oversight.
Sources
- StatPearls. Hyperbaric Oxygen Therapy Contraindications. NCBI Bookshelf, NBK557661. Updated 2025. NCBI
- Wang D. Value of hyperbaric oxygen in adjuvant treatment of patients with stable chronic obstructive pulmonary disease. Central Plains Med J. 2017. DOI: 10.3760/CMA.J.ISSN.1674-4756.2017.05.010
- Effects of HBOT on lungs histopathology in COPD animal models. Trop J Nat Prod Res. 2024. DOI: 10.26538/tjnpr/v8i9.15
- Novikova TA, et al. HBOT as pulmonary rehabilitation for post-COVID patients with comorbid COPD. 2025.
- American Lung Association. Learn About COPD. 2024. Lung.org
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
